"Innovation needs to happen, so we can minimize the number of patients who lose the battle to cancer.” Mohamed Zaki, M.D., Ph.D., vice president, global head of hematology development, AbbVie
Globally, cancer is one of the most difficult challenges in health care today, impacting patients, their families and their communities. Our scientists and researchers are committed to improving the standard of care.
Their mission is bold, yet still personal as they’ve witnessed their patients and even their loved ones battle the disease, the AbbVie in Oncology team continues working to deliver new, impactful therapies.
Accelerating the Transformation of Cancer Care
When I started in oncology, a close family member was diagnosed with breast cancer. It made me realize the importance of science and understanding how these tumors are growing and evolving.
Anahita Bhathena, Ph.D., translational oncology, AbbVie
We’re curious and we’re basically problem solvers. So, day to day we’re in there trying to solve that next problem.
Saul Rosenberg, Ph.D., senior director of oncology research, AbbVie
We’re not only extending life, but we’re boosting quality of life among those cancer patients. Some of the things that we’ve done within AbbVie have benefitted patients in a way that’s transformative.
Steve Davidsen, Ph.D., vice president of oncology discovery, AbbVie
Our scientists put their focus into three groups: regulated cell death, immune-oncology, and tumor specific antigens.
Researchers are examining regulated cell death, trying to exploit the pathways a cell uses to induce its own demise in an orderly, programmed manner.
Immune-oncology is an area of research where scientists explore ways the body unleashes its own immune system to eradicate cancer cells.
Through our work in tumor-specific antigens, teams are researching targeted deliveries to cancer cells that could induce less collateral damage to the patient.
Our hope is cancer, in the future, is not something that limits the life span of many patients, but is something that can be managed and potentially cured.
Danelle James, head of clinical science, Pharmacyclics, an AbbVie Company
